Immune ResponseOLIVENCT02872311

Open-Label Influenza Vaccine Evaluation

A study testing High Dose Influenza vaccine, Adjuvanted Influenza vaccine and Standard Dose Influenza vaccine in people with Immune Response, run by Marshfield Clinic Research Foundation at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 65 to 74 years
Conditions the study is for: Immune Response
What is being tested?: High Dose Influenza vaccine, Adjuvanted Influenza vaccine and Standard Dose Influenza vaccine
Type of treatment: Vaccines, Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 179 participants
Where: 1 siteUnited States
Study dates: Sep 2016to Sep 2018
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 65 to 74 years
All sexes
No healthy volunteers
Older adult

Who may be able to join

Age 65-74 years at the time of study enrollment and are ambulatory and live in selected Wisconsin community or surrounding communities.
Willing and able to give informed consent prior to study enrollment
Able to comply with study requirements.

Who cannot join

Prior receipt of 2016-17 influenza vaccine
Current participation in another clinical trial
Presence of a contraindication to influenza vaccine

Trial locations and contacts

1 site in 1 country.

United States1 site

Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449

Other trials in United States

About this study

Official title: Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)

This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons. Participants will be randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will receive the same vaccination in the second year and the third arm will be randomized again to 1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood draws for a total of 6 draws over 18 months.

Conditions: Immune Response
Being tested: High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Keywords: Vaccine, Influenza, High Dose, Adjuvanted, Recombinant
Medical subject headings: Influenza, Human

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

High Dose Influenza vaccineBiological
Also called Fluzone HD
Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
Adjuvanted Influenza vaccineBiological
Also called FluAd
Licensed and FDA approved FluAd vaccine to be administered to study participants
Standard Dose Influenza vaccineBiological
Also called Fluvirin Standard Dose
Licensed and FDA approved Fluvirin vaccine to be administered to study participants
Recombinant Influenza vaccineBiological
Also called FluBlok
Licensed and FDA approved FluBlok vaccine to be administered to study participants

Study groups in NCT02872311
Study group	Role	What they receive
High Dose Influenza Vaccine	Active comparator	This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study. Receives: Biological: High Dose Influenza vaccine
Adjuvanted Influenza Vaccine	Active comparator	This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study. Receives: Biological: Adjuvanted Influenza vaccine
Standard Dose Influenza Vaccine+HD	Active comparator	This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study. Receives: Biological: High Dose Influenza vaccine; Biological: Standard Dose Influenza vaccine
Standard Dose Influenza Vaccine +Adj	Active comparator	This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study. Receives: Biological: Adjuvanted Influenza vaccine; Biological: Standard Dose Influenza vaccine
Standard Dose Influenza Vaccine+Recomb	Active comparator	This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study. Receives: Biological: Standard Dose Influenza vaccine; Biological: Recombinant Influenza vaccine

What is being measured

The primary outcome is the main question the study is designed to answer.

HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17
Measured: Year 1, Day 28 post vaccination
HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17
Measured: Year 1, Day 182 post vaccination
HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17
Measured: Year 1, Day 365 post vaccination
HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18
Measured: Year 2, Day 28 post vaccination
HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18
Measured: Year 2, Day 182 post vaccination

Secondary outcomes (13)

HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination
Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 28 days post vaccination, 2016-17
Measured: Year 1, Day 28 post vaccination
HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination
Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 182 days post vaccination, 2016-17
Measured: Year 1, Day 182 post vaccination
HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination
Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 365 days post vaccination, 2016-17
Measured: Year 1, Day 365 post vaccination
MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination
Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2016-17
Measured: Year 1, Day 28 post vaccination
MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination
Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 182 days post vaccination, 2016-17
Measured: Year 1, Day 182 post vaccination
MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination
Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 365 days post vaccination, 2016-17
Measured: Year 1, Day 365 post vaccination
MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination
Microneutralization antibody titers to vaccine virus (A/Hong Kong (siat cell) among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2017-18
Measured: Year 2, Day 28 post vaccination
HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 28 days post vaccination 2017-18
Measured: Year 2, Day 28 post vaccination
HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 182 days post vaccination 2017-18
Measured: Year 2, Day 182 post vaccination
HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination
Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 28 days after vaccination, 2017-18
Measured: Year 2, Day 28 post vaccination
HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination
Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 182 days after vaccination, 2017-18
Measured: Year 2, Day 182 post vaccination
Number of Participants With Vaccine Failure, Year 1
Number of Participants with Vaccine Failure in Year 1 by vaccine type
Measured: Year 1, Post season
Number of Participants With Vaccine Failure, Year 2
Number of Participants with Vaccine Failure in Year 2 by two-year vaccine history
Measured: Year 2, Post season

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Sep 2016Sep 2018

First posted19 Aug 2016 (estimated)
Study startSep 2016
Primary completionApr 2018
Study completionSep 2018

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Immune ResponseStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 179 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02872311
Sponsor's protocol ID: MCL10416
Acronym: OLIVE
Status last verified: Nov 2025
First submitted: 16 Aug 2016
Last updated: 10 Dec 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
Individual data sharing: No

Publications

McLean HQ, Levine MZ, King JP, Flannery B, Belongia EA. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years. Vaccine. 2021 Dec 3;39(49):7146-7152. doi: 10.1016/j.vaccine.2021.10.072. Epub 2021 Nov 10.
PubMed 34774360

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 1
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Metastatic Malignant Solid Neoplasm, Lymphoma
Active, not recruitingObservational study
Host Response to Infection and Treatment in Filarial Diseases
Filariasis, Helminthiasis
RecruitingPhase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
RecruitingPhase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Not yet recruitingObservational study
BCMA Polymorphisms in Patients With Multiple Myeloma
Multiple Myeloma

All Immune Response trials

Study at a glance

From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)
ClinicalTrials.gov ID: NCT02872311
Acronym / sponsor ID: OLIVE / MCL10416
Conditions: Immune Response
Keywords: Vaccine, Influenza, High Dose, Adjuvanted, Recombinant
Study type: Interventional
Recruitment status: Completed
Enrolment: 179 participants (actual)
Lead sponsor: Marshfield Clinic Research FoundationUniversity, hospital or other
Collaborators: Centers for Disease Control and Prevention
Study start: Sep 2016
Primary completion: Apr 2018 (actual)
Study completion: Sep 2018 (actual)
First posted: 19 Aug 2016 (estimated)
Results: Posted 19 Dec 2019

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 5

Arm	Type	Receives
High Dose Influenza Vaccine	Active comparator	Biological: High Dose Influenza vaccineThis group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza Vaccine	Active comparator	Biological: Adjuvanted Influenza vaccineThis group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Standard Dose Influenza Vaccine+HD	Active comparator	Biological: High Dose Influenza vaccine, Biological: Standard Dose Influenza vaccineThis group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza Vaccine +Adj	Active comparator	Biological: Adjuvanted Influenza vaccine, Biological: Standard Dose Influenza vaccineThis group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza Vaccine+Recomb	Active comparator	Biological: Standard Dose Influenza vaccine, Biological: Recombinant Influenza vaccineThis group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.

Who may qualify

Ages: 65 to 74 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Older adult

Key inclusion criteria (3 listed)

Age 65-74 years at the time of study enrollment and are ambulatory and live in selected Wisconsin community or surrounding communities.
Willing and able to give informed consent prior to study enrollment
Able to comply with study requirements.

Key exclusion criteria (3 listed)

Prior receipt of 2016-17 influenza vaccine
Current participation in another clinical trial
Presence of a contraindication to influenza vaccine

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
High Dose Influenza vaccineAlso: Fluzone HDLicensed and FDA approved Fluzone HD vaccine to be administered to study participants	Biological	High Dose Influenza Vaccine, Standard Dose Influenza Vaccine+HD
Adjuvanted Influenza vaccineAlso: FluAdLicensed and FDA approved FluAd vaccine to be administered to study participants	Biological	Adjuvanted Influenza Vaccine, Standard Dose Influenza Vaccine +Adj
Standard Dose Influenza vaccineAlso: Fluvirin Standard DoseLicensed and FDA approved Fluvirin vaccine to be administered to study participants	Biological	Standard Dose Influenza Vaccine +Adj, Standard Dose Influenza Vaccine+HD, Standard Dose Influenza Vaccine+Recomb
Recombinant Influenza vaccineAlso: FluBlokLicensed and FDA approved FluBlok vaccine to be administered to study participants	Biological	Standard Dose Influenza Vaccine+Recomb

Primary outcome

HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination
Time frame: Year 1, Day 28 post vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17
HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination
Time frame: Year 1, Day 182 post vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17
HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination
Time frame: Year 1, Day 365 post vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17
HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination
Time frame: Year 2, Day 28 post vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18
HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination
Time frame: Year 2, Day 182 post vaccination
Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18

13 secondary outcomes

HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination
Time frame: Year 1, Day 28 post vaccination
HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination
Time frame: Year 1, Day 182 post vaccination
HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination
Time frame: Year 1, Day 365 post vaccination
MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination
Time frame: Year 1, Day 28 post vaccination
MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination
Time frame: Year 1, Day 182 post vaccination
MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination
Time frame: Year 1, Day 365 post vaccination
MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination
Time frame: Year 2, Day 28 post vaccination
HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination
Time frame: Year 2, Day 28 post vaccination
HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination
Time frame: Year 2, Day 182 post vaccination
HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination
Time frame: Year 2, Day 28 post vaccination
HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination
Time frame: Year 2, Day 182 post vaccination
Number of Participants With Vaccine Failure, Year 1
Time frame: Year 1, Post season
Number of Participants With Vaccine Failure, Year 2
Time frame: Year 2, Post season

Results and safety

Results posted to the registry on 19 Dec 2019, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
High Dose Influenza Vaccine	59	55
Adjuvanted Influenza Vaccine	60	58
Standard+High Dose	20	19
Standard+Adjuvanted	20	20
Standard+Recombinant	20	20

Primary outcome: HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination

Time frame: Year 1, Day 28 post vaccination. Geometric mean (95% Confidence Interval). Unit: Titer

Measure	High Dose Influenza Vaccine n = 55	Adjuvanted Influenza Vaccine n = 58
A/H1/California	175 (128 to 239)	117 (87 to 159)
A/H3/Hong Kong	144 (102 to 201)	118 (87 to 159)
B/Brisbane(Victoria)	166 (117 to 236)	81 (59 to 112)

Population analysed: This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.

Primary outcome: HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination

Time frame: Year 1, Day 182 post vaccination. Geometric mean (95% Confidence Interval). Unit: Titer

Measure	High Dose Influenza Vaccine n = 55	Adjuvanted Influenza Vaccine n = 58
A/H1/California	83 (62 to 110)	56 (41 to 77)
A/H3/Hong Kong	83 (60 to 113)	68 (51 to 91)
B/Brisbane(Victoria)	61 (43 to 88)	44 (33 to 60)

Population analysed: This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.

Primary outcome: HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination

Time frame: Year 1, Day 365 post vaccination. Geometric mean (95% Confidence Interval). Unit: Titer

Measure	High Dose Influenza Vaccine n = 55	Adjuvanted Influenza Vaccine n = 58
A/H1/California	54 (40 to 72)	44 (32 to 60)
A/H3/Hong Kong	75 (55 to 103)	75 (57 to 100)
B/Brisbane(Victoria)	36 (25 to 52)	24 (17 to 32)

Population analysed: This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.

Primary outcome: HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination

Time frame: Year 2, Day 28 post vaccination. Geometric mean (95% Confidence Interval). Unit: Titer

Measure	High Dose Influenza Vaccine n = 55	Adjuvanted Influenza Vaccine n = 58
A/H1/Michigan	83 (64 to 107)	101 (74 to 139)
A/H3/Hong Kong	158 (114 to 220)	158 (123 to 203)
B/Brisbane(Victoria)	63 (46 to 87)	45 (33 to 61)

Population analysed: This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.

13 secondary outcomes are reported in the full results.

Adverse events

Time frame: 18 months of the study. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
High Dose Influenza Vaccine	0 of 55 (0%)	0 of 55 (0%)	2 of 55
Adjuvanted Influenza Vaccine	0 of 58 (0%)	0 of 58 (0%)	0 of 58
Standard Dose Influenza Vaccine+HD	0 of 19 (0%)	0 of 19 (0%)	0 of 19
Standard Dose Influenza Vaccine +Adj	0 of 20 (0%)	0 of 20 (0%)	0 of 20
Standard Dose Influenza Vaccine+Recomb	0 of 20 (0%)	0 of 20 (0%)	0 of 20

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 34774360McLean HQ, Levine MZ, King JP, Flannery B, Belongia EA. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years. Vaccine. 2021 Dec 3;39(49):7146-7152. doi: 10.1016/j.vaccine.2021.10.072. Epub 2021 Nov 10.
Individual participant dataSharing planned: No

Related trials for Immune Response

RecruitingPhase 1
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Metastatic Malignant Solid Neoplasm, Lymphoma
Active, not recruitingObservational study
Host Response to Infection and Treatment in Filarial Diseases
Filariasis, Helminthiasis
RecruitingPhase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
RecruitingPhase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Not yet recruitingObservational study
BCMA Polymorphisms in Patients With Multiple Myeloma
Multiple Myeloma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Dec 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination (time frame: Year 1, Day 28 post vaccination). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02872311, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.